Literature DB >> 2953326

Cognitive impairment in patients with multiple sclerosis and mild physical disability.

W van den Burg, A H van Zomeren, J M Minderhoud, A J Prange, N S Meijer.   

Abstract

Forty mildly disabled and clinically stable patients with multiple sclerosis (MS), representative of the corresponding population in Northern Holland, with disability Status Scale scores evenly distributed within the 1 to 4 range, were compared with 40 age-, sex-, and education-matched normal controls on a battery of neuropsychological tests. Apart from impairments in perceptual-motor functioning, generally mild deficiencies in intelligence and, specifically, in memory were displayed in the MS group. Attentional processes appeared uncompromised. Increasing fatigue during testing could not account for poor performance. The memory deficits could be attributed to poor initial learning, although there was also evidence suggesting that accelerated forgetting of what had been learned may appear with the progression of MS. Seven patients (17.5%), as compared with none of the controls, were classified by blind clinical judgement of test performance as definitely impaired.

Entities:  

Mesh:

Year:  1987        PMID: 2953326     DOI: 10.1001/archneur.1987.00520170024017

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

1.  Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.

Authors:  K Lauer; W Firnhaber
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

2.  Korsakoff's syndrome as the initial presentation of multiple sclerosis.

Authors:  A Vighetto; N Charles; M Salzmann; C Confavreux; G Aimard
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

3.  Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging.

Authors:  C Mariani; E Farina; S F Cappa; G P Anzola; L Faglia; L Bevilacqua; R Capra; F Mattioli; L A Vignolo
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

4.  Neuropsychological assessment in patients with relapsing-remitting multiple sclerosis and mild functional impairment: correlation with magnetic resonance imaging.

Authors:  G P Anzola; L Bevilacqua; S F Cappa; R Capra; L Faglia; E Farina; G Frisoni; C Mariani; M P Pasolini; L A Vignolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

5.  Verbal episodic memory in 426 multiple sclerosis patients: impairment in encoding, retrieval or both?

Authors:  H Brissart; E Morele; C Baumann; M Debouverie
Journal:  Neurol Sci       Date:  2012-01-13       Impact factor: 3.307

6.  Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis.

Authors:  M S A Deloire; E Salort; M Bonnet; Y Arimone; M Boudineau; H Amieva; B Barroso; J-C Ouallet; C Pachai; E Galliaud; K G Petry; V Dousset; C Fabrigoule; B Brochet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

7.  SPECT, MRI and cognitive functions in multiple sclerosis.

Authors:  C Pozzilli; D Passafiume; S Bernardi; P Pantano; C Incoccia; S Bastianello; L Bozzao; G L Lenzi; C Fieschi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

8.  Structural brain correlates of anterograde memory deficits in multiple sclerosis.

Authors:  M Brainin; G Goldenberg; C Ahlers; T Reisner; A Neuhold; L Deecke
Journal:  J Neurol       Date:  1988-07       Impact factor: 4.849

9.  Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study.

Authors:  A Feinstein; L D Kartsounis; D H Miller; B D Youl; M A Ron
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

10.  Attention related performance in two cognitively different subgroups of patients with multiple sclerosis.

Authors:  P Kujala; R Portin; A Revonsuo; J Ruutiainen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.